These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6457169)

  • 61. Moxalactam therapy for gram-negative bacillary meningitis.
    Rahal JJ
    Rev Infect Dis; 1982; 4 Suppl():S606-9. PubMed ID: 6218572
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Clinical examination of cefoperazone in pediatrics (author's transl)].
    Matsuda H; Yoshida T; Kagata N; Niino S
    Jpn J Antibiot; 1980 Sep; 33(9):935-40. PubMed ID: 6452543
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical evaluation of moxalactam in the treatment of respiratory tract infections, hepatobiliary infections, and septicemia.
    Saito A
    Rev Infect Dis; 1982; 4 Suppl():S623-8. PubMed ID: 6218575
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hemorrhage, diarrhea, and superinfection associated with the use of moxalactam.
    Panwalker AP; Rosenfeld J
    J Infect Dis; 1983 Jan; 147(1):171-2. PubMed ID: 6218209
    [No Abstract]   [Full Text] [Related]  

  • 65. The new cephalosporins and penicillins.
    Weinstein AJ
    Compr Ther; 1982 Feb; 8(2):26-31. PubMed ID: 6279354
    [No Abstract]   [Full Text] [Related]  

  • 66. Moxalactam treatment of anaerobic infections in cancer patients.
    Lagast H; Meunier-Carpentier F; Klastersky J
    Antimicrob Agents Chemother; 1982 Oct; 22(4):604-10. PubMed ID: 6217784
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of moxalactam.
    Reed MD; Bertino JS; Aronoff SC; Speck WT; Blumer JL
    Clin Pharm; 1982; 1(2):124-34. PubMed ID: 6224626
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Clinical studies on 6059-S for acute peritonitis. Clinical effect and tissue concentration (author's transl)].
    Hashimoto I; Sawada Y; Nakamura T; Mikami J; Bekki E; Hirasawa S; Abe H; Katoh H; Matsuda S
    Jpn J Antibiot; 1981 Apr; 34(4):623-30. PubMed ID: 6457171
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical evaluation of moxalactam.
    Mathisen GE; Meyer RD; Thompson JM; Finegold SM
    Antimicrob Agents Chemother; 1982 May; 21(5):780-6. PubMed ID: 6213198
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of intraabdominal infection with moxalactam.
    Murphy TF; Barza M
    Rev Infect Dis; 1982; 4 Suppl():S670-5. PubMed ID: 6218581
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Moxalactam therapy of infections caused by cephalothin-resistant bacteria: influence of serum inhibitory activity on clinical response and acquisition of antibiotic resistance during therapy.
    Platt R; Ehrlich SL; Afarian J; O'Brien TF; Pennington JE; Kass EH
    Antimicrob Agents Chemother; 1981 Sep; 20(3):351-5. PubMed ID: 6458233
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Pharmacokinetics and results of clinical administration of CS-1170. II. Results of clinical administration of CS-1170 (author's transl)].
    Cho K; Takimoto M; Yoshioka H; Nanbu H
    Jpn J Antibiot; 1979 Jan; 32(1):6-10. PubMed ID: 423367
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Clinical results of latamoxef on pertussis].
    Minamitani M; Hachimori K; Nakazawa S; Sato H; Narita A; Hirama Y; Nakazawa S; Chikaoka H; Motohiro T; Nishiyama T; Fujimoto T; Ishimoto K; Tominaga K; Yamashita F; Matsuo H; Koga Y; Eto Y; Matsuyuki M; Yuasa T; Tanaka Y; Nagayama K; Shimada Y; Aramaki S; Takajo N; Araki H; Kawano Y
    Jpn J Antibiot; 1983 Feb; 36(2):233-40. PubMed ID: 6304367
    [No Abstract]   [Full Text] [Related]  

  • 74. [Evaluation of cefotetan in pediatrics].
    Aso K; Nakashima T; Miyachi Y; Nishikawa K; Ogawa A; Yafuso M; Kuno K
    Jpn J Antibiot; 1983 Jun; 36(6):1295-300. PubMed ID: 6581334
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Clinical evaluation of cefotetan in pediatrics].
    Meguro H; Ozawa S; Togo T; Kim B; Arimasu O; Yonezawa H; Fujii R
    Jpn J Antibiot; 1983 Jun; 36(6):1262-70. PubMed ID: 6581331
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacokinetic and clinical evaluation of moxalactam in infants and children.
    Latif R; Thirumoorthi MC; Buckley JA; Kobos DM; Aravind MK; Kauffman RE; Dajani AS
    Dev Pharmacol Ther; 1981; 3(4):222-31. PubMed ID: 6212231
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of serious infections with moxalactam.
    Ribner BS; Raeder R; Becker TM; Freimer EH
    Am J Med; 1983 Mar; 74(3):396-400. PubMed ID: 6219576
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Clinical efficacy of T-1982 (cefbuperazone) for infections of children].
    Kurashige T; Kitamura I; Ogura H; Wakiguchi H; Morita H; Kuramitsu M; Kuroiwa Y; Tone Y; Mino M
    Jpn J Antibiot; 1983 Apr; 36(4):877-80. PubMed ID: 6876377
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ceftriaxone--and more to come.
    Marks MI
    J Pediatr; 1983 Jul; 103(1):70-2. PubMed ID: 6306195
    [No Abstract]   [Full Text] [Related]  

  • 80. Moxalactam therapy vs. standard antimicrobial therapy for selected serious infections.
    Oblinger MJ; Bowers JT; Sande MA; Mandell GL
    Rev Infect Dis; 1982; 4 Suppl():S639-49. PubMed ID: 6218577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.